METADATE CD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for METADATE CD (METADATE CD).
Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. The precise mechanism for treating ADHD is not fully understood.
| Metabolism | Primarily hepatic via carboxylesterase CES1A1 to the inactive metabolite ritalinic acid; minor pathways include hydroxylation (CYP2D6) and microsomal oxidation. |
| Excretion | Renal: 78-97% as metabolites (primarily ritalinic acid), unchanged drug <1%; fecal: <2% |
| Half-life | Terminal elimination half-life: 6.8 hours (range 4.5-10.3 hours) for methylphenidate; clinical context: supports twice-daily dosing regimen |
| Protein binding | Methylphenidate: 10-33% bound to albumin; low binding, minimal displacement interactions |
| Volume of Distribution | Volume of distribution: 0.2-0.5 L/kg; indicates distribution into total body water and tissues |
| Bioavailability | Oral (extended-release): approximately 30% (range 11-52%) due to first-pass metabolism |
| Onset of Action | Oral (extended-release): 1-2 hours for peak plasma concentration; clinical effect observed within 1 hour |
| Duration of Action | Duration of clinical effect: 10-12 hours for the extended-release formulation; designed to cover the school day with a single morning dose |
| Molecular Weight | 269.77 |
20-60 mg orally once daily in the morning
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No specific dose adjustment available; use with caution in severe renal impairment (GFR <30 mL/min) |
| Liver impairment | No specific dose adjustment for Child-Pugh; however, caution in severe hepatic impairment |
| Pediatric use | For ADHD in children ≥6 years: starting dose 20 mg once daily, titrated by 20 mg/week to max 60 mg/day |
| Geriatric use | Limited data; start at lower end of dosing range (20 mg daily) and monitor closely for adverse effects |
| 1st trimester | Risk of major congenital malformations not significantly increased based on limited human data; however, risk of intrauterine growth restriction (IUGR) and preterm birth. |
| 2nd trimester | Same as t1. Consider non-pharmacologic treatment first due to potential for IUGR, preterm birth, and neonatal adverse effects. |
| 3rd trimester | Exposure may lead to neonatal withdrawal syndrome including irritability, feeding difficulties, and respiratory distress. Avoid use near term. |
Clinical note
Comprehensive clinical and safety monograph for METADATE CD (METADATE CD).
| Placental transfer | Crosses the placenta; detectable in cord blood and neonatal plasma. |
| Breastfeeding | Methylphenidate is excreted into breast milk in low concentrations (infant dose about 0.7% of maternal weight-adjusted dose); no adverse effects reported in infants, but caution advised due to potential for irritability, insomnia, and growth suppression. |
■ FDA Black Box Warning
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including METADATE CD, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
| Serious Effects |
Hypersensitivity to methylphenidate or any componentConcurrent use or within 14 days of MAOI therapyGlaucomaTics or family history of Tourette syndromeSevere hypertensionHyperthyroidism
| Precautions | Abuse and dependence, Serious cardiovascular events (sudden death, stroke, MI) in patients with structural cardiac abnormalities or other serious heart problems, Blood pressure and heart rate increase, Psychiatric adverse events (exacerbation of psychosis, mania, aggression), Long-term suppression of growth in children, Seizures (may lower seizure threshold), Peripheral vasculopathy including Raynaud's phenomenon, Visual disturbances (difficulty with accommodation, blurred vision), Hematologic effects (leukopenia, anemia, thrombocytopenia) |
| Food/Dietary | No specific food restrictions. However, high-fat meals may delay absorption and reduce peak concentration. Avoid alcohol due to potential for increased CNS depression and altered drug release. Grapefruit juice may increase methylphenidate levels; avoid excessive consumption. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal malformations (e.g., cardiac, skeletal) at high doses. Second and third trimesters: Risk of preterm birth, low birth weight, and neonatal withdrawal (tachycardia, irritability). |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and weight gain. Fetal ultrasound for growth and anomalies. Neonatal monitoring for withdrawal symptoms and cardiovascular effects post-delivery. |
| Fertility Effects | No specific human data on fertility impairment. Animal studies show decreased implantation and increased fetal resorption at high doses. Caution in women planning pregnancy. |
| Clinical Pearls | METADATE CD is a methylphenidate extended-release formulation with bimodal release: immediate release beads (30% of dose) for rapid onset and delayed release beads (70%) for sustained effect. Do not crush or chew capsules; may open and sprinkle contents on applesauce. Monitor for hypertension, tachycardia, and growth suppression in children. Avoid use in patients with glaucoma, motor tics, or family history of Tourette's syndrome. Use cautiously with MAOIs (contraindicated within 14 days), anticoagulants, and antihypertensives. |
| Patient Advice | Take METADATE CD exactly as prescribed, usually once daily in the morning. Do not take later in the day to avoid insomnia. · Swallow capsules whole with liquid. If you have trouble swallowing, you may open the capsule and sprinkle the beads on a spoonful of applesauce, then swallow immediately without chewing. · Do not crush, chew, or divide the capsule contents. The beads are specially coated for extended release. · Avoid alcohol while taking this medication because it can increase side effects and alter drug release. · Common side effects include decreased appetite, trouble sleeping, stomach pain, nausea, and headache. Contact your doctor if symptoms are severe or persistent. · Report any signs of heart problems such as chest pain, shortness of breath, or fainting, especially during exercise. · This medication may cause dizziness or blurred vision; avoid driving or hazardous activities until you know how it affects you. · Store at room temperature away from moisture and heat. Keep out of reach of children. |